Arrowhead Pharmaceuticals (ARWR) has just combined a third major approval for REDEMPLO (plozasiran) with fresh obesity trial data and sizeable new financings, giving investors several material updates to digest at once.

These approvals and obesity trial updates come after a sharp 79.98% 3 month share price return and a very large 1 year total shareholder return of 248.32%. However, the year to date share price return of a 2.27% decline suggests momentum has cooled slightly after a strong run into recent news.

If this kind of cardiometabolic and obesity pipeline interests you, it could be a good moment to scan other healthcare stocks that might be riding similar treatment themes.

With Arrowhead now carrying three major approvals for REDEMPLO, fresh obesity data, and roughly US$825 million of recent financing behind it, is a US$66 share price still underestimating what comes next, or is future growth already fully priced in?

Most Popular Narrative: 3% Overvalued

At a last close of US$66.25 against a narrative fair value of about US$64.08, Arrowhead is framed as slightly ahead of that central estimate, with the story leaning heavily on future cardiometabolic and RNAi opportunities.

Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, positions the company to capitalize on rising demand for therapies driven by an aging population and increasing prevalence of chronic and genetic diseases, which could significantly accelerate revenue growth as approvals and launches materialize.

Curious how this story supports a premium valuation? The key ingredients are future margins, revenue resets, and an earnings multiple rarely seen outside fast growing sectors.

Result: Fair Value of $64.08 (OVERVALUED)

However, this story still hinges on successful late stage trial readouts and partner follow through. As a result, any clinical or collaboration setbacks could quickly challenge today’s premium.

Build Your Own Arrowhead Pharmaceuticals Narrative

If this narrative does not quite fit your view, you can review the same data, frame your own thesis in minutes, and Do it your way.

A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop with a single stock. Use the Simply Wall Street Screener to spot other opportunities efficiently.

• Target potential mispricing by checking out these 868 undervalued stocks based on cash flows that might offer more attractive entry points based on their cash flow profiles.
• Capture trends in machine learning and automation by scanning these 24 AI penny stocks that could benefit from growing interest in AI technologies.
• Strengthen your income stream by reviewing these 12 dividend stocks with yields > 3% that offer yields above 3% and may complement growth focused holdings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.